Smith & Nephew (NYSE:SNN) 2025 Capital Markets Day December 11, 2025 09:00 AM ET Company ParticipantsCaitlin Roberts - DirectorRohit Kashyap - President of World BusinessHadi El-Heneidi - Senior Director of Global MarketingDeepak Nath - CEOJohn Rogers - CFOIseult McMahon - Equity Research AssociateScott Schaffner - President of Sports MedicineSteven Hass - Orthopedic SurgeonCathy Dalene - SVP of Global Wound CareMayank Shandil - Global Senior VPMike Ast - Director of Asc StrategyAnil Ranawat - Orthopedic Su ...

Financial Data and Key Metrics Changes - Consolidated net sales for Q2 were $53.2 million, a sequential improvement from $50.7 million in Q1, but a decline from $55.7 million in the prior year period [26] - Consolidated gross profit for the quarter was $5.8 million, or 10.9% of sales, compared to $6 million, or 10.8% of sales in the prior year [26] - SG&A expense for the quarter was $8.7 million, reflecting a 7% improvement compared to the prior year [27] - Loss from operations was $3.5 million, an improvement from a loss of $5.4 million in the prior year [27] - Adjusted EBITDA was negative $1 million, an improvement from negative $1.1 million in the prior year [28] Business Line Data and Key Metrics Changes - Bedding segment sales for Q2 were $30.8 million, up approximately 10% sequentially and over 2% year-over-year [30] - Gross profit in the bedding segment was $3.1 million, or 10.1% of sales, a 200 basis points improvement from the prior year [31] - Upholstery segment sales for Q2 were $22.4 million, flat sequentially but down approximately 12% year-over-year [31] - Gross profit in the upholstery segment was $3.6 million, or 16.1% of sales, down from $4.3 million, or 16.9% of sales in the prior year [31] Market Data and Key Metrics Changes - The home furnishings industry continues to face significant challenges, with low consumer confidence and high levels of unsold homes impacting sales [7][20] - The bedding market is showing signs of stabilization, with expectations for an increase in unit activity driven by historical product replacement cycles [19][20] - Upholstery business remains impacted by weak consumer sentiment and housing market conditions, particularly affecting lower and middle-income segments [21][22] Company Strategy and Development Direction - The company is focused on winning market share and adjusting its cost structure to achieve profitability in the current market cycle [8] - A comprehensive restructuring project has been completed, expected to yield approximately $11 million in annualized cost savings [14][18] - The integration of the bedding and upholstery divisions aims to create a unified Culp-branded business, enhancing operational efficiency [15][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging demand environment for home furnishings but expects steady consolidated sales performance in the near term [36] - The company anticipates continued improvement in operating loss and near break-even to positive Adjusted EBITDA for Q3 [36] - Management remains cautious about the timing of market recovery but is positioning the company to capitalize on future demand increases [45][46] Other Important Information - The company has a net debt position of $7.6 million and continues to manage liquidity and capital expenditures aggressively [32][34] - The company is owed approximately $4.7 million from the sale of its Canada facility, expected to be received in Q3 [36] Q&A Session Summary Question: What is the realization status of the cost savings? - Management indicated that significant savings are being realized, with most expected to be fully realized by Q4 [41][44] Question: What will be the incremental margin on the next point of sales growth? - Management confirmed that there is built-up leverage to capitalize on any increase in sales, with fixed costs in place to retain a significant portion of incremental dollars [47][48] Question: What is the status of the new tariffs in Turkey and Haiti? - Management explained that recent tariff changes have created challenges, but the company is well-positioned to navigate these issues [49][50]

Summary of AC Immune Conference Call - December 11, 2025 Company Overview - **Company**: AC Immune (NasdaqGM: ACIU) - **Focus**: Development of active immunotherapies for neurodegenerative diseases, particularly targeting alpha-synuclein in Parkinson's disease and tau/amyloid-beta in Alzheimer's disease [4][27] Key Industry Insights - **Parkinson's Disease**: Second most common neurodegenerative disorder, fastest growing neurological disease, affecting approximately 1% of the population over 65 years [9] - **Market Need**: Significant unmet need for disease-modifying therapies in Parkinson's disease, with current treatments primarily symptomatic [28] Core Points from the Call 1. **Vaccine Phase Two Trial Results**: - Positive interim results from the phase two trial of ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease patients [2][24] - The trial included 34 subjects aged 40-75 with early-stage Parkinson's disease [13] 2. **Safety and Tolerability**: - ACI-7104 demonstrated a favorable safety profile with no serious adverse events related to the study drug [24] - Common adverse events included injection site reactions (56%), headache (14%), and fatigue (12%) [15] 3. **Immunogenicity**: - ACI-7104 achieved a 100% responder rate, with significant increases in antibody titers observed after each immunization [16][24] - Antibodies generated were shown to cross the blood-brain barrier, indicating potential efficacy in targeting alpha-synuclein in the brain [17] 4. **Biomarker Analysis**: - Interim analysis showed stabilization of total alpha-synuclein levels in cerebrospinal fluid (CSF) in the treatment group, suggesting target engagement [25] - Neurofilament light chain (NFL) levels remained stable in the treatment group, indicating a potential slowing of neurodegeneration [20] - DaT-SPECT imaging indicated no progression in dopamine transporter levels in the treatment group, contrasting with expected declines in the placebo group [21][32] 5. **Clinical Measures**: - MDS-UPDRS Part III scores, which assess motor symptoms, showed minimal changes in the treatment group over 74 weeks, suggesting stabilization of motor function [23][30] 6. **Future Development Plans**: - AC Immune is considering an accelerated development pathway towards registration, potentially skipping part two of the trial [46] - Plans to include U.S. sites in future studies and explore the inclusion of tracer molecules in the next study [47] Additional Insights - **Market Potential**: Partner programs have generated over CHF 450 million in payments, with potential for an additional CHF 4 billion in milestone payments and royalties [5] - **Long-term Vision**: AC Immune aims to pioneer precision prevention strategies for neurodegenerative diseases, leveraging their active immunotherapy platform [27] Conclusion - The interim results from the ACI-7104 trial indicate promising safety, immunogenicity, and potential disease-modifying effects in early Parkinson's disease, positioning AC Immune favorably in the neurodegenerative disease market [26][50]

Summary of American Superconductor (AMSC) Conference Call on Contrafo Acquisition Company and Industry - **Company**: American Superconductor Corporation (AMSC) - **Acquisition Target**: Contrafo Industria de Transformadores Eléctricos S.A. - **Industry**: Power transformers manufacturing, specifically for utility and industrial customers - **Market Context**: Brazilian transformer market valued at $1.5 billion annually, with significant growth expected in Latin America Key Points and Arguments 1. **Acquisition Announcement**: AMSC announced the acquisition of Contrafo, a Brazilian company specializing in large power and distribution transformers, expected to generate approximately $55 million in revenue for the calendar year 2025 [2][4] 2. **Financial Details**: The acquisition involves a payment of roughly $55 million in cash, $78 million in stock, and an additional $29 million for land, totaling about $162 million [5][10] 3. **Operational Capacity**: Contrafo has a production facility of 125,000 sq ft and a workforce of 580 employees, with a backlog of $85 million and a 12-month backlog of $55 million [4][5] 4. **Market Opportunity**: Brazil is the largest electricity market in Latin America, with local governments planning over $20 billion in investments for grid modernization, expected to quadruple in the next decade [6][7] 5. **Product Portfolio Expansion**: The acquisition allows AMSC to extend its product offerings to include transformers for the distribution grid up to 15 MVA and large power transformers up to 250 MVA, addressing critical needs for power utilities [8][9] 6. **Immediate Accretion**: The acquisition is expected to be immediately accretive to AMSC's earnings, with operating margins exceeding 20% and gross margins in line with AMSC's levels [4][20] 7. **Growth Strategy**: AMSC plans to prioritize growth in Brazil, with potential future expansion into broader Latin American markets and possibly North America [17][28] 8. **Cultural Integration**: AMSC has experience in managing multilingual operations and aims to integrate Contrafo's family-oriented culture into its existing framework [39][40] 9. **Future Capacity Expansion**: AMSC is considering future capital expenditures for expanding Contrafo's manufacturing capabilities, leveraging the acquired land for growth [33][34] 10. **Long-term Vision**: The acquisition is seen as a strategic move to enhance AMSC's market presence and product offerings, with a focus on leveraging existing technologies and customer relationships [41][42] Other Important Insights - **Market Dynamics**: The Brazilian transformer market is expected to grow significantly, driven by government investments and increasing demand from electric utilities [6][7] - **Earn-out Structure**: The acquisition includes an earn-out provision that could result in additional payments if Contrafo doubles its revenue within three years [34][48] - **Data Center Opportunities**: While immediate focus is on utility demand, there is potential for future involvement in the growing data center market in Brazil [58][60] This summary encapsulates the key aspects of the conference call regarding AMSC's acquisition of Contrafo, highlighting the strategic importance of the deal and the anticipated benefits for both companies.

Weyerhaeuser Company (NYSE:WY) 2025 Investor Day Summary Company Overview - Weyerhaeuser has over 125 years of experience as a leader in sustainable forestry, land management, and wood products manufacturing [2][3] - The company is positioned for accelerated growth through innovation, operational excellence, and leveraging emerging technologies [2][3] Key Themes and Growth Strategy - The focus is on two main themes: building a strong operational foundation and launching a multi-year growth program [4][5] - The growth program aims to deliver an incremental $1.5 billion of Adjusted EBITDA by 2030 over a 2024 baseline, improving cash flow per share and reducing volatility [5][25] Timberlands Business - Weyerhaeuser is the largest private owner of timberlands in North America, with 10.4 million acres in the U.S. and 13 million acres in Canada [6] - The timberlands business generates approximately $1 billion of EBITDA per year, providing a sustainable base for dividends and financial strength [15] - The company has a competitive advantage through its scale, quality, and diversity of its timber portfolio [11][48] Operational Excellence and Cost Discipline - Weyerhaeuser has focused on cost discipline and operational excellence, achieving industry-leading margins and strong brand recognition [7][23] - The company has returned nearly $7.5 billion to shareholders over the past decade, including a 5% annual increase in base dividends [10][24] Market Conditions and Cyclicality - The company acknowledges the cyclicality of the housing market and has strategies in place to navigate market fluctuations [17][18] - Weyerhaeuser believes that cyclical businesses can be profitable with a well-aligned strategy, focusing on cost and operational excellence [17][18] Long-term Targets and Achievements - Weyerhaeuser has successfully met or exceeded aggressive targets set during previous investor days, including acquiring $1.2 billion of high-quality timberlands [20][21] - The climate solutions business achieved its goal of $100 million in Adjusted EBITDA by 2025, demonstrating strong growth potential [21] Growth Initiatives - The growth initiatives include ongoing acquisitions and dispositions, increasing harvest volume, and new demand and product uplift [50][54] - The company is exploring opportunities in the southern export market, capitalizing on declining global timber supplies and increasing demand from countries like India [58][60] Wood Products Business - Weyerhaeuser has one of the largest and most cost-competitive wood products businesses in North America, with a strong portfolio in engineered wood products, lumber, and MDF [62][63] - The company is focused on leveraging its integrated platform to drive growth and improve margins across its wood products business [63] Conclusion - Weyerhaeuser is well-positioned for future growth with a strong operational foundation, innovative strategies, and a commitment to sustainability [34][61] - The company aims to deliver significant value to shareholders through its growth initiatives and disciplined capital allocation approach [26][30]

Summary of Bristol-Myers Squibb Company (NYSE:BMY) Hematology Drug Development Update Company Overview - **Company**: Bristol-Myers Squibb Company (BMS) - **Focus**: Hematology treatments, specifically advancements in drug development for multiple myeloma and other hematological diseases Key Points and Arguments Strategic Approach to Drug Development - BMS emphasizes a strategic approach in drug development focusing on hematology, leveraging strong scientific expertise and innovative research platforms [4][5] - The company is committed to three key priorities: science, execution, and value, ensuring that resources are allocated to the most promising growth opportunities [6][7] Hematology Leadership - BMS has a strong legacy in hematology, being the first company with two approved CAR-T cell therapies (Abecma and Breyanzi) in distinct disease areas [8] - The company is advancing its leadership in targeted protein degradation and cell therapy, with a focus on innovative treatments for hematological diseases [9][10] Pipeline and Portfolio - BMS has a diverse hematology portfolio, including multiple myeloma, leukemias, lymphomas, and anemia, with critical assets in both late and early stages [11] - The company is focusing on two pivotal-stage CELMoDs (Iberdomide and Mezigdomide) and next-generation CAR-T assets [12][13] CELMoDs Development - Iberdomide and Mezigdomide are positioned to become foundational treatments in multiple myeloma, with enhanced potency and immune stimulation [12][13] - Iberdomide has shown a 95% overall response rate and a 68% complete response rate in early trials, indicating significant clinical benefits [15][16] - Mezigdomide demonstrated over 80% overall response rates in pretreated patients, showcasing its potential in combination therapies [17][18] Combination Therapies - BMS is exploring novel combinations of CELMoDs with other therapies, including CAR-T and bispecifics, to enhance treatment efficacy [19][20] - The company is optimistic about the potential of CELMoDs to improve outcomes when used as preconditioning agents or maintenance therapies post-CAR-T infusion [20][21] CAR-T Therapy Advancements - ArloCell, a GPRC5D targeting CAR-T, has shown promising results with over 90% overall response rates in heavily pretreated patients [22][23] - The dual-targeting BCMA and GPRC5D CAR-T is expected to provide more durable and potent activity compared to single-target therapies [24][25] Lymphoma Assets - BMS is developing novel lymphoma assets, including golcadomide and a BCL6 targeting ligand-directed degrader, which have shown promising efficacy results [26][27][31] - The company aims to improve cure rates in large B-cell lymphoma and pursue functional cures in follicular lymphoma [26][27] Regulatory and Market Considerations - BMS is preparing for potential accelerated approval of Iberdomide based on MRD results, with ongoing discussions with health authorities [41][42] - The approval of Blenrep is viewed positively, providing additional treatment options for patients, although its use may be limited in earlier lines of therapy [52][53] Future Outlook - BMS anticipates significant data readouts in the coming years that will shape the future growth of the company and its hematology portfolio [32][33] - The company is positioned to transform the treatment landscape for hematological diseases, with a focus on innovative therapies that address unmet patient needs [32][33] Additional Important Insights - The company is utilizing AI and machine learning to enhance its R&D processes and expedite treatment delivery [6] - BMS is committed to ensuring that no patient segment is left behind, focusing on personalized treatment approaches [25][32] - The evolving treatment landscape for multiple myeloma is complex, but BMS aims to integrate its portfolio to provide comprehensive care [47][50]

Financial Data and Key Metrics Changes - Consolidated net sales from continuing operations for Q3 2026 were $70.7 million, a decrease of $11.9 million or 14.4% compared to the prior year period [2][3] - Gross profit decreased by $2.4 million, but gross margin improved to 25.6%, up from 24.8% last year [3] - Operating loss from continuing operations totaled $16.3 million, and net loss from continuing operations was $12.5 million or $1.18 per diluted share [5][6] - Year-to-date consolidated net sales from continuing operations were $211.1 million, down $22 million or 9.4% compared to the prior year [6][7] - Gross margin for the nine-month period improved to 25%, up from 23.9% in the prior year [7] Business Line Data and Key Metrics Changes - Domestic Upholstery sales increased by 3% in Q3, while Hooker Branded sales rose by 1.1% [3][15] - Hooker Branded reported GAAP operating income of $711,000 for Q3 compared to a loss of $1.5 million [15] - Domestic Upholstery backlog fell from year-end but rose year-over-year on a 3.5% increase in orders [17] Market Data and Key Metrics Changes - The hospitality business experienced a decline due to the timing of shipments, with several large projects shipping in the previous year's third quarter [3][4] - Discontinued operations for Pulaski Furniture and Samuel Lawrence Furniture saw combined net sales decline by $11.3 million in Q3 and $22.5 million year-to-date [8][17] Company Strategy and Development Direction - The company is focusing on becoming a higher margin, design-driven entity by exiting low-margin, tariff-sensitive categories [9][10] - The launch of the Margaritaville license collection is seen as a significant organic growth opportunity, with initial purchase commitments exceeding historical levels [10][11] - A new share repurchase program has been authorized, allowing the company to repurchase up to $5 million of outstanding shares, while also recalibrating the dividend [19][20] Management Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the retail environment, noting that while peak sales periods are positive, consistent demand is needed [28][46] - The company believes it is better positioned to improve profitability even in a prolonged downturn due to a more efficient cost structure and sharper portfolio focus [22][46] Other Important Information - The company recorded $22.1 million in non-cash impairment charges, which included $14.5 million on Sunset West goodwill [4][5] - Cash and cash equivalents stood at $1.4 million, with $63.8 million in available borrowing capacity at quarter end [18][19] Q&A Session Summary Question: Impact of shipment timing in hospitality division - Management noted that the hospitality brand had significant contributions from large hotel projects last year, which did not repeat this quarter [24] Question: Sustainability of sales gains in core business - Management expressed confidence in sustaining sales gains due to product momentum and significant product introductions [25][26] Question: Revenue from discontinued operations - Management indicated that discontinued operations were a significant drag on operating income, with further details expected in upcoming filings [29] Question: Margin profile for Margaritaville line - Management suggested that the margin profile could be estimated based on historical Hooker Branded margins [41] Question: Future cost-cutting measures - Management indicated that additional savings would be identified in future announcements, with a focus on the divestiture of brands creating opportunities [43] Question: Signs of demand recovery - Management reported cautious optimism from retail partners but did not identify specific green shoots indicating demand recovery [46]

Valvoline Investor Update Summary Company Overview - **Company**: Valvoline (NYSE: VVV) - **Industry**: Automotive Services, specifically oil change and vehicle maintenance - **Date of Update**: December 11, 2025 Core Points and Arguments Strategic Focus - Valvoline aims to clarify its strategy and financial plan to enhance long-term shareholder value [4][9] - The company has a history of nearly 160 years, focusing on quality and innovation in automotive care [4] - Transitioned to a pure-play retail services provider by divesting its global products business, allowing focus on high-growth, high-margin retail services [5] Financial Commitments - Valvoline targets net sales growth of 9%-11% over the next three years, driven by same-store sales growth and new store openings [20] - The company emphasizes disciplined capital allocation, focusing on high-quality network growth and returning excess cash to shareholders through share repurchases [11] Market Position and Growth Potential - Valvoline holds a 6% market share in oil changes, indicating significant room for expansion [24] - The average age of vehicles is increasing, leading to higher maintenance needs, which benefits Valvoline's service offerings [58] - The company plans to open over 2,900 new stores by the end of 2028, with a long-term goal of 3,500+ locations [24] Customer Experience and Operational Excellence - Valvoline boasts a high customer retention rate, with over 80% of customers being repeat visitors [15] - The company has a strong Net Promoter Score (NPS) above 80%, indicating high customer satisfaction [12] - Operational efficiencies have led to a 270 basis point increase in four-wall margins in mature stores [44] Innovation and Technology - Valvoline is investing in technology to enhance customer experience, including mobile service delivery and improved in-store processes [27][54] - The company utilizes a robust data environment to optimize service delivery and customer interactions [18][53] Franchise Partnerships - Valvoline's franchise partners have an average tenure of 26 years and have committed over $1 billion in future growth, contributing to the company's expansion strategy [19] Additional Important Insights - The company has faced regulatory challenges with the FTC regarding large acquisitions, which may limit future large transactions in the industry [10] - Valvoline's operational model is designed to be replicable and scalable, ensuring consistent service quality across locations [46] - The company is adapting its service menu to meet evolving customer needs, including the introduction of premium synthetic lubricants [29] Conclusion - Valvoline presents a compelling investment opportunity due to its established market position, strong operational performance, and significant growth potential in a fragmented market [34] - The company is committed to delivering attractive shareholder returns while maintaining a focus on customer satisfaction and operational excellence [34]

Financial Performance - Q3 2025 - Revenues reached $41.4 million, a 25.5% increase compared to $33.0 million in Q3 2024, driven by drybulk fleet additions[5] - Operating income increased significantly to $10.3 million in Q3 2025, a roughly 72% increase ($4.3 million) compared to Q3 2024 and a 22.6% increase ($1.9 million) compared to Q2 2025[6] - EBITDA for Q3 2025 was $17.9 million, a 46.7% increase compared to $12.2 million in Q3 2024[6] - Net income for Q3 2025 was $11.0 million, compared to $10.0 million in Q3 2024[6] Financial Performance - 9M 2025 - Net income for 9M 2025 reached $35.0 million[6] - EBITDA for 9M 2025 was $49.7 million[6] - Operating cash flow generation for 9M 2025 was $57.0 million[6] Liquidity and Fleet - Cash and cash equivalents, including time deposits, amounted to approximately $100 million as of September 30, 2025, with a current cash base of about $172 million[6] - The company concluded a capital raise of $60 million through a registered direct equity offering, intended for further fleet growth[6] - Fleet operational utilization for Q3 2025 was 88.7%, compared to 65.6% in Q3 2024[6] - Approximately 75% of the total fleet calendar days were dedicated to time charter activity, while about 25% were dedicated to spot activity[4]

GENERATIVE AI DRUG CREATION ABS-201 KOL SEMINAR ABSCI CORPORATION 2025 ALL RIGHTS RESERVED Disclaimers Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predic ...